362 related articles for article (PubMed ID: 29744485)
1. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
Chen Q; Yang Y; Lin X; Ma W; Chen G; Li W; Wang X; Yu Z
Chem Commun (Camb); 2018 May; 54(42):5369-5372. PubMed ID: 29744485
[TBL] [Abstract][Full Text] [Related]
2. Imidazole modified Pt(iv) prodrug-loaded multi-stage pH responsive nanoparticles to overcome cisplatin resistance.
Kang X; Wang Y; Chen Z; Wu Y; Chen H; Yang X; Yu C
Chem Commun (Camb); 2020 Sep; 56(76):11271-11274. PubMed ID: 32830841
[TBL] [Abstract][Full Text] [Related]
3. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
[TBL] [Abstract][Full Text] [Related]
4. Cyclodextrin capped gold nanoparticles as a delivery vehicle for a prodrug of cisplatin.
Shi Y; Goodisman J; Dabrowiak JC
Inorg Chem; 2013 Aug; 52(16):9418-26. PubMed ID: 23889547
[TBL] [Abstract][Full Text] [Related]
5. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR
Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526
[TBL] [Abstract][Full Text] [Related]
6. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer.
Li C; Li T; Huang L; Yang M; Zhu G
Chem Asian J; 2019 May; 14(9):1570-1576. PubMed ID: 30843348
[TBL] [Abstract][Full Text] [Related]
7. Toward overcoming cisplatin resistance via sterically hindered platinum(II) complexes.
Yu H; Gou S; Wang Z; Chen F; Fang L
Eur J Med Chem; 2016 May; 114():141-52. PubMed ID: 26974381
[TBL] [Abstract][Full Text] [Related]
8. Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.
Wu R; Zhang Z; Wang B; Chen G; Zhang Y; Deng H; Tang Z; Mao J; Wang L
Drug Des Devel Ther; 2020; 14():2249-2261. PubMed ID: 32606595
[TBL] [Abstract][Full Text] [Related]
9. A platinum prodrug conjugated with a photosensitizer with aggregation-induced emission (AIE) characteristics for drug activation monitoring and combinatorial photodynamic-chemotherapy against cisplatin resistant cancer cells.
Yuan Y; Zhang CJ; Liu B
Chem Commun (Camb); 2015 May; 51(41):8626-9. PubMed ID: 25898264
[TBL] [Abstract][Full Text] [Related]
10. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
11. Dual-targeting antitumor conjugates derived from platinum(IV) prodrugs and microtubule inhibitor CA-4 significantly exhibited potent ability to overcome cisplatin resistance.
Huang X; Wang M; Wang C; Hu W; You Q; Yang Y; Yu C; Liao Z; Gou S; Wang H
Bioorg Chem; 2019 Nov; 92():103236. PubMed ID: 31494328
[TBL] [Abstract][Full Text] [Related]
12. Platinum(IV) Complexes of
Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
[TBL] [Abstract][Full Text] [Related]
13. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
Shi H; Cheng Q; Yuan S; Ding X; Liu Y
Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
[TBL] [Abstract][Full Text] [Related]
14. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
Yu C; Ding B; Zhang X; Deng X; Deng K; Cheng Z; Xing B; Jin D; Ma P; Lin J
Biomaterials; 2018 Feb; 155():112-123. PubMed ID: 29175080
[TBL] [Abstract][Full Text] [Related]
15. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
16. An oxaliplatin(iv) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment.
Lim WQ; Phua SZF; Chen H; Zhao Y
Chem Commun (Camb); 2018 Nov; 54(90):12762-12765. PubMed ID: 30370905
[TBL] [Abstract][Full Text] [Related]
17.
Lee VEY; Lim ZC; Chew SL; Ang WH
Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
[TBL] [Abstract][Full Text] [Related]
18. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D
Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707
[TBL] [Abstract][Full Text] [Related]
19. Overcoming tumor resistance to cisplatin by cationic lipid-assisted prodrug nanoparticles.
Cao ZT; Chen ZY; Sun CY; Li HJ; Wang HX; Cheng QQ; Zuo ZQ; Wang JL; Liu YZ; Wang YC; Wang J
Biomaterials; 2016 Jul; 94():9-19. PubMed ID: 27088406
[TBL] [Abstract][Full Text] [Related]
20. Alternative mechanism of action of the DNP Pt
Krasnovskaya O; Spector D; Erofeev A; Gorelkin P; Akasov R; Skvortsov D; Trigub A; Vlasova K; Semkina A; Zyk N; Beloglazkina E; Majouga A
Dalton Trans; 2021 Jun; 50(23):7922-7927. PubMed ID: 34037020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
